Growth factors for early decompensated cirrhosis
Treatments studied
This study tests whether a combination of two medicines (G-CSF and darbepoetin) given in one or more cycles can improve the body's immune and metabolic health in people with early-stage decompensated cirrhosis (advanced liver disease with mild complications). It compares these treatments with standard medical care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have cirrhosis that has caused ascites (fluid buildup in the belly), but it is not severe or complicated
- You have not had alcohol in the last 3 months
- You have not had bleeding from your esophagus in the last 6 weeks
- You have not had confusion or coma due to liver disease in the last 6 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether umbilical cord stem cells are safe for people with advanced (decompensated) hepatitis B cirrhosis. It mainly looks at safety and whether symptoms or quality of life improve after standard care has not helped enough.
This trial tests whether giving a combination of two medicines (GCSF and Darbepoetin) one time or multiple times can help people with early-stage liver cirrhosis who have started to develop complications. The goal is to see if this treatment can improve liver function and delay the need for a transplant.
This trial tests umbilical-cord stem cells to see if they can improve outcomes in people with decompensated (worsening) cirrhosis. You may be considered if your liver disease is moderate to severe (MELD 15–30) and you do not have certain high-risk problems right now.
This study looks at new blood markers to better predict recovery in patients hospitalized for complications of cirrhosis (like fluid buildup, confusion, or bleeding). You may qualify if you were recently hospitalized for these issues and are expected to go home soon.
This trial tests if injecting donated liver cells into the main artery feeding the liver can help people with decompensated cirrhosis. It aims to see if this treatment is safe and might improve liver function.
This trial tests an experimental drug for people with severe alcoholic hepatitis that did not improve with steroids. Participants should have a moderate level of organ failure, but not require a breathing tube or kidney dialysis.
Hear when a new Decompensated Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.